Armata Pharmaceuticals
ARMP
26 hedge funds and large institutions have $1.08M invested in Armata Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 9 reducing their positions, and 0 closing their positions.
8% more funds holding
Funds holding: 24 → 26 (+2)
1.79% less ownership
Funds ownership: 3.84% → 2.05% (-1.8%)
58% less capital invested
Capital invested by funds: $2.57M → $1.08M (-$1.49M)
78% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 9
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$51.7K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$41K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$711 |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$317 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$1.26M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$49.8K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$44K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$13.6K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$9.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $1 | – | – | – |
|
ARMP Hedge Fund Activity: Q1 2025 in Review
26 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q1 2025, worth a combined $1.08M — down 58% from $2.57M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ARMP positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 9 trimmed.
The largest buyer was Vanguard Group, adding an estimated $51.7K. The largest seller was Bank of America, cutting an estimated $1.26M.
- 26 institutional investors held Armata Pharmaceuticals (ARMP) as of Q1 2025, up from 24 in Q4 2024.
- Funds reported $1.08M of Armata Pharmaceuticals stock for Q1 2025, down 58% quarter-over-quarter.
- 2 funds opened new Armata Pharmaceuticals positions in Q1 2025 and 0 closed out, a net change of +2 holders.
- The largest Armata Pharmaceuticals buyer in Q1 2025 was Vanguard Group, an estimated $51.7K added.
- The largest Armata Pharmaceuticals seller in Q1 2025 was Bank of America, an estimated $1.26M sold.
Based on aggregated 13F filings for Q1 2025.